Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evoq RemediesBOM:543500 -1.13%60 Days Payable is 439.33 as of Mar. 2026, which is 235% above its 10-year median of 131.04. GuruFocus rates BOM:543500 with a GF Score™ of 60/100 and a GF Value™ of ₹12.94 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 116 Medical Distribution companies, Evoq Remedies ranks worse than 93.1% on this metric.
The historical rank and industry rank for Evoq Remedies's Days Payable or its related term are showing as below:
BOM:543500'
s Days Payable Range Over the Past 10 Years
Min: 6.35 Med: 131.04 Max: 321.89
Current: 23.98
During the past 8 years, Evoq Remedies's highest Days Payable was 321.89. The lowest was 6.35. And the median was 131.04.
BOM:543500's Days Payable is ranked worse than 93.1% of 116
companies
in the Medical Distribution industry
Industry Median: 77.285
vs BOM:543500: 23.98
Evoq Remedies's Days Payable
increased
from Mar. 2025 (34.73) to Mar. 2026 (439.33).
It may suggest that Evoq Remediesdelayed paying its suppliers.
The historical data trend for Evoq Remedies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543500 vs MCK, COR, CAH: Days Payable Comparison
For the Medical Distribution subindustry, Evoq Remedies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoq Remedies Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Evoq Remedies's Days Payable distribution charts can be found below:
* The bar in red indicates where Evoq Remedies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Evoq Remedies's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoq Remedies (BOM:543500) has a Days Payable of 439.33 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evoq Remedies and its competitors. This is 235% above median its historical median of 131.04. Over the past decade, Evoq Remedies' Days Payable has ranged from 6.35 to 321.89. According to the industry distribution chart, Evoq Remedies ranks #108 out of 116 companies in the Medical Distribution industry, placing it in the top 93.1%.
Is Evoq Remedies' Days Payable too high?
Evoq Remedies' current Days Payable of 439.33 is 235% above median its 10-year median of 131.04. Over the past 10 years, this metric has ranged from a low of 6.35 to a high of 321.89. The Medical Distribution industry median Days Payable is 77.29. Evoq Remedies' value of 439.33 is 468.5% above this industry median. Based on the distribution chart, Evoq Remedies ranks #108 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Evoq Remedies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evoq Remedies' Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Evoq Remedies ranks #108 out of 116 companies for Days Payable. This places Evoq Remedies in the lower half of its industry. The industry median Days Payable is 77.29. Evoq Remedies' value of 439.33 is 468.5% above this benchmark. Historically, Evoq Remedies' own Days Payable has ranged from 6.35 to 321.89 over the past decade. While the company's 10-year median is 131.04 vs. the industry median of 77.29, Evoq Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 77.29, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evoq Remedies's current Days Payable of 439.33 is 468.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evoq Remedies and its competitors. For the Medical Distribution industry, the median Days Payable is 77.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evoq Remedies's current Days Payable is 439.33, which is 235% above median its own 10-year median of 131.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evoq Remedies stock overvalued right now?
Based on GuruFocus' analysis, Evoq Remedies (BOM:543500) is currently considered Possible Value Trap. The stock's GF Value™ is ₹12.94, compared to a current price of ₹1.83 — trading 85.9% below its estimated fair value. The current Days Payable is 439.33, which is 235% above median its 10-year median of 131.04 and 468.5% above the Medical Distribution industry median of 77.29. Evoq Remedies' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Evoq Remedies (BOM:543500), the current Days Payable is 439.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evoq Remedies (BOM:543500) Overvalued in 2026?
Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued.
The current stock price of ₹1.83 is trading 85.9% below its estimated GF Value™ of ₹12.94.
GuruFocus considers Evoq Remedies to be Possible Value Trap.
Key valuation signals for BOM:543500:
Days Payable: 439.33 (235% above median its 10-year median of 131.04)
GF Value™: ₹12.94 vs. price of ₹1.83 (85.9% below fair value)
Industry Position: 468.5% above the Medical Distribution median (#108 of 116)
No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
60GF Score
Get the complete analysis for BOM:543500
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543500 has been successfully added to your 
